Day: January 5, 2023

VANCOUVER, British Columbia, Jan. 05, 2023 (GLOBE NEWSWIRE) — American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | OTCQB:LIACF | Frankfurt:5LA1) is pleased to announce it has received approval to list its common shares (the “Common Shares”) on the Nasdaq Capital Market (“Nasdaq”). Trading is scheduled to commence on Nasdaq at the open of markets on Tuesday January 10, 2023, under the symbol “AMLI”. Concurrently with the listing, the Common Shares will cease to be quoted on the OTCQB® Venture Market but will continue to trade on the TSX Venture Exchange. Simon Clarke, CEO of American Lithium stated, “We are very pleased to be joining Nasdaq as this listing marks a major milestone for the Company and is a testament to the dedication and hard work of our team. We are confident this listing will elevate American...

Thumzup Media Corporation The Thumzup mobile appAvailable in the App Store and Google Play, Thumzup Aims to Democratize the Social Media Branding Industry by Incentivizing Virtually Everyone to Post about Brands and Businesses through Major Social Media Outlets Los Angeles, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Thumzup Media Corporation (“Thumzup”) (OTCQB:TZUP) is excited to announce that its revolutionary platform, available in the App Store and Google Play, is aiming to democratize the $208 billion dollar advertising industry[1], similar to how Uber and Airbnb disrupted the transportation and hotel industries, respectively. The Thumzup mobile app, which is available for download in the App Store and Google Play, incentivizes virtually everyone to become social media advocates for the brands they enjoy by paying...

DENVER, Jan. 05, 2023 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen weeks ended November 26, 2022. First Quarter Summary:(1)Net sales increased 7.0% Net income(2) of $35.9 million versus $21.2 million Earnings per diluted share (“EPS”)(2) of $0.36 versus $0.22 Adjusted Diluted EPS(3) of $0.42 versus $0.43 Adjusted EBITDA(4) of $60.8 million versus $65.6 millionReaffirm fiscal year 2023 Net Sales and Adjusted EBITDA(4) outlook:Net sales expected to increase slightly greater than the Company’s long-term algorithm of 4-6%, including a headwind of almost 1 percentage point related to the frozen pizza licensing Adjusted EBITDA(4,5) anticipated...

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce positive results from its APH-19 Phase 3 trial of lomitapide for the treatment of Homozygous Familial Hypercholesterolemia (HoFH) in children aged 5-17 years. Dr Joe Wiley, CEO of Amryt Pharma, commented: “We are encouraged by these important additional results regarding the efficacy of lomitapide in treating children with HoFH. This is good news for patients and their families.”   Top Line ResultsA total of 46 pediatric patients were enrolled, with 43 patients completing the run-in phase and entering the efficacy...

OLNEY, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc. (Nasdaq: SASR) will announce its fourth quarter earnings on Thursday, January 26, 2023. The company will hold a conference call that day at 2:00 p.m. (ET) to discuss results and answer questions. The conference call will be webcast live through the Sandy Spring Bank website. Those who wish to participate in order to ask questions may do so by calling 1- 844-200-6205; please use Access Code: 970945. Those who wish to listen to the call should go to the Investor Relations page of www.sandyspringbank.com and log on 10 minutes ahead of the scheduled start of the call. An internet-based replay will be available on the Investor Relations page of the website until February 9, 2023. A telephone voice replay will also be available during that same time period at 1-866-813-9403....

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA. An audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage...

IRVINE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Industrial Internet of Things (IoT) and the Intelligent IT market, today announced that its CFO, Jeremy Whitaker, will present at the 25th Annual Needham Virtual Growth Conference on Jan. 11, 2023 at 2:15 p.m. Eastern Standard Time. A webcast of the presentation will be available live via the link below. In addition, a replay of the presentation will remain available at the webcast link for 30 days after the presentation. Webcast Link: https://wsw.com/webcast/needham128/ltrx/2301602 Lantronix management will also hold in-person, one-on-one meetings on Jan. 10 and 11. To book a one-on-one meeting, please contact your Needham salesperson.        About Lantronix Lantronix Inc. is a global provider...

VANCOUVER, British Columbia, Jan. 05, 2023 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce the appointments of Rob Henderson as Vice President, Technical Services and Kevin MacKenzie as Vice President, Corporate Development & Investor Relations. Patrick Downey, President and CEO stated, “I am extremely pleased that Rob and Kevin have joined our team. Both are well-regarded industry professionals with significant worldwide experience in management, operations, exploration, capital markets and M&A. Rob is a proven mining executive with extensive global operations and development experience including West Africa as VP Technical Services for Kinross Gold. Rob will lead Orezone’s technical teams, ensuring ongoing operational excellence, and provide technical...

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, M.D., Ph.D., who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy (GA). “Caroline is a world-renowned retina specialist who has been at the forefront of retina research and patient care for over 25 years, and we are thrilled to welcome her to Apellis,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder of Apellis. “Caroline’s expertise and deep understanding of GA will be a tremendous asset as...

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2023. “2022 marked a successful year of continued clinical and corporate accomplishments for ALX Oncology. Marked by steady progress in the clinical development of our lead program, evorpacept, for the treatment of multiple solid tumor indications and hematological malignancies, we expanded clinical development of evorpacept in new indications and combinations. These included a Phase 1 trial in urothelial cancer (“UC”) in combination with PADCEV®, an investigator-sponsored Phase 2 trial in refractory microsatellite stable metastatic...